Daiichi Sankyo Co., Ltd.

This study tests a drug called pexidartinib in 40 adults with a rare joint tumor (TGCT) that causes severe symptoms and cannot be helped by surgery. The main goal is to see if the drug shrinks the tumors after 25 weeks of treatment. Participants take the drug daily and are monito…

This study looks at the long-term safety and effectiveness of a drug called DS-5141b in people with Duchenne muscular dystrophy (DMD). It includes 8 participants who already completed an earlier study of the same drug. Researchers will track side effects and measure changes in mu…

This study tests an experimental drug called DS-1001b in 25 people with a type of slow-growing brain tumor (grade II glioma) that has a specific IDH1 gene mutation. Participants have not had chemotherapy or radiation before. The goal is to see if the drug can shrink or control th…

This study tests an experimental drug called DS-3201b in about 100 adults with non-Hodgkin lymphoma whose cancer has come back or stopped responding to standard treatments. The main goals are to find a safe dose and see how well the drug works. The study also checks how the drug …

This study tests a drug called pexidartinib in 9 adults in Japan who have a rare, non-cancerous joint tumor (TGCT) that causes severe problems and cannot be helped by surgery. The goal is to see if the drug can shrink the tumor and improve joint movement, while checking for side …

This study tests a new drug called DS-1062a in people with advanced solid tumors, including certain lung and breast cancers that have not responded to standard treatments. It is the first time this drug is being used in humans, and the main goals are to check its safety and find …